Filtered By:
Drug: Diovan

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 78 results found since Jan 2013.

Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | PMC:PMC10293657 | DOI:10.3346/jkms.2023.38.e202
Source: Journal of Korean Medical Science - June 27, 2023 Category: Biomedical Science Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research

A review of the use of Angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications.
CONCLUSIONS: Data supporting the use of ARBs for reducing cardiovascular events in patients with essential hypertension without compelling indications are limited and inconclusive. More studies are needed before ARBs can be routinely recommended as first-line therapy for hypertension management in patients without other compelling indications. PMID: 23585649 [PubMed - in process]
Source: The Annals of Pharmacotherapy - May 1, 2013 Category: Drugs & Pharmacology Authors: Zaiken K, Hudd TR, Cheng JW Tags: Ann Pharmacother Source Type: research

Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk.
CONCLUSION: In the high-risk hypertensive patients of the VALUE trial achieving more frequently BP <140/90 mmHg, but not <130/80 mmHg, showed principally the same protective effect on overall and cause-specific cardiovascular outcomes in patients with diabetes mellitus and in the general high-risk hypertensive population. PMID: 33403890 [PubMed - as supplied by publisher]
Source: Blood Pressure - January 8, 2021 Category: Hematology Tags: Blood Press Source Type: research

Angiotensin Receptor-Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials
In conclusion, this meta-analysis found no association between ARNI therapy and improved ASCVD events in patients with HF.PMID:37619492 | DOI:10.1016/j.amjcard.2023.07.154
Source: Atherosclerosis - August 24, 2023 Category: Cardiology Authors: Lis Victoria Ravani Douglas Mesadri Gewehr Pedro Calomeni Mateus de Miranda Gauza Jussara Pereira Rhanderson Cardoso Henrique Barbosa Ribeiro Edimar Bocchi Source Type: research

Telmisartan, valsartan lower risk of CVD complications in diabetics
Compared with irbesartan, the use of telmisartan and valsartan lowered the risk of hospital admission for MI, stroke, or heart failure by 15% and 14%, respectively. The reduction was driven primarily by a reduction in the risk of heart-failure hospitalizations.
Source: theHeart.org - July 8, 2013 Category: Cardiology Source Type: news

Two ARBs Lower Risk of CVD Complications in DiabeticsTwo ARBs Lower Risk of CVD Complications in Diabetics
Compared with irbesartan, the use of telmisartan and valsartan lowered the risk of hospital admission for MI, stroke, or heart failure by 15% and 14%, respectively. The reduction was driven primarily by a reduction in the risk of heart-failure hospitalizations. Heartwire
Source: Medscape Today Headlines - July 8, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Diabetics Taking Certain Blood Pressure Drugs At Lower Risk Of Heart Disease
Two drugs, telmisartan and valsartan, which are used to reduce blood pressure in people with diabetes, are associated with a lower risk of hospitalization for heart attack, stroke or heart failure, according to a study published in CMAJ (Canadian Medical Association Journal). For people with type 2 diabetes, disease-related vascular illnesses are the main causes of death. Angiotensin-receptor blockers including telmisartan, valsartan, candesartan, irbesartan and losartan, are generally used interchangeably to control blood pressure...
Source: Health News from Medical News Today - July 10, 2013 Category: Consumer Health News Tags: Hypertension Source Type: news

Protective effect of valsartan for stroke in Japanese subjects: an analysis of Jikei Heart Study: Retraction
No abstract available
Source: Journal of Hypertension - October 8, 2013 Category: Cardiology Tags: Retractions Source Type: research

“Fere libenter homines id quod volunt credunt”: Apprehension for the stroke reduction in the KYOTO HEART Study on the basis of meta-regression from the evidence
“Fere libenter homines id quod volunt credunt (Men willingly believe what they wish).”De Bello Gallico, Book III, Chapter 18 The KYOTO HEART Study [NCT00149227] was designed to examine whether valsartan (angiotensin-receptor blocker [ARB]) added to the conventional anti-hypertensive treatment influences the cardiovascular events in the high-risk Japanese patients with uncontrolled hypertension. The authors used the Prospective, Randomized, Open-labeled, Blinded Endpoints (PROBE) , two-arm parallel treatment group comparison study design with a response-dependent dose titration scheme. Main results of the KYOTO HEART S...
Source: International Journal of Cardiology - December 16, 2013 Category: Cardiology Authors: Hisato Takagi, Takuya Umemoto, for the ALICE (All-Literature Investigation of Cardiovascular Evidence) Group Tags: Editorials Source Type: research

Comment NAVIGATOR: physical activity for cardiovascular health?
In The Lancet, Thomas Yates and colleagues report new findings from the NAVIGATOR trial, a multicentre, international, randomised, placebo-controlled trial that examined the effect of nateglinide, valsartan, or both, on cardiovascular events in patients with impaired glucose tolerance and either existing cardiovascular disease or at least one additional risk factor. The results of this cohort analysis of the association between daily ambulatory activity, as assessed by pedometer, and a composite of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke, show a graded and independent inverse...
Source: LANCET - March 21, 2014 Category: Journals (General) Authors: Giuseppe Pugliese, Stefano Balducci Tags: Comment Source Type: research

Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
ConclusionsIn VALIANT, the risk of HF following MI was higher in women than men after adjusting for age and comorbidities, although the risk of other fatal and non‐fatal outcomes were similar. The higher long‐term risk of HF in women appears to be independent of the extent of left ventricular systolic dysfunction or remodelling compared with men.
Source: European Journal of Heart Failure - February 6, 2015 Category: Cardiology Authors: Carolyn S. P. Lam, Margaret McEntegart, Brian Claggett, Jiankang Liu, Hicham Skali, Eldrin Lewis, Lars Køber, Jean Rouleau, Eric Velazquez, Rob Califf, John J. McMurray, Marc Pfeffer, Scott Solomon Tags: Original Article Source Type: research

Humid heat exposure induced oxidative stress and apoptosis in cardiomyocytes through the angiotensin II signaling pathway
Abstract Exposure to humid heat stress leads to the initiation of serious physiological dysfunction that may result in heat-related diseases, including heat stroke, heat cramp, heat exhaustion, and even death. Increasing evidences have shown that the humid heat stress-induced dysfunction of the cardiovascular system was accompanied with severe cardiomyocyte injury; however, the precise mechanism of heat stress-induced injury of cardiomyocyte remains unknown. In the present study, we hypothesized that humid heat stress promoted oxidative stress through the activation of angiotensin II (Ang II) in cardiomyocyte...
Source: Heart and Vessels - May 1, 2015 Category: Cardiology Source Type: research